ABBVIE Stock- CDMO Sterling acquires ADC Bio, ramping up capacity for antibody-drug conjugate manufacturing work – Endpoints News
Sterling Pharma Solutions has announced the acquisition of ADC Bio, a UK-based company that specializes in antibody drug conjugates. ADC’s Wales manufacturing facility will rebrand to become part of the Sterling network, the companies said.
ADC will start work as part of the Sterling network as early as 2022. The move allows Sterling to integrate the new facility’s highly potent API capabilities to develop and manufacture toxin linkers, according to a release.
“This investment provides us with the opportunity to offer a wider portfolio of services to our customers in the fast growing ADC and bioconjugation market, as well as providing additional services to existing ADC Bio customers,” CEO Kevin Cook said in a statement.
Sterling acquired a former Alcami facility in Germantown, Wisconsin, in September 2020. In 2019, it acquired a Cary, North Carolina facility that used to belong to CiVentiChem. That was its first US facility, and it kept aboard all 23 of those employees.
The Germantown facility houses state-of-the-art cGMP development, scale-up and manufacturing facilities. Germantown has also specialist expertise in handling technologies including plant-scale hydrogenation and cryogenic reactions, according to the company. At the time, Sterling noted that the move was part of a $46 million push over the last four years.
The CDMO employs 750 people across the world now, according to Sterling.
ADCs have become a hot-button area for investment in recent years. One of the leaders in that space, Daiichi Sankyo recently pledge to dump $13.6 billion into ADC and bispecific antibody technologies over the next five years, including $2.3 billion on supply chain.
Meanwhile, in mid-March, Pfizer inked a deal with Cambridge, MA-based Pyxis Oncology. Pfizer received up-front payment, milestones and some equity in Pyxis, while Pyxis gained rights to Pfizer’s ADC platform. Pfizer will out-liscense PYX-201 and PYX-203, and give Pyxis a license for its platform.
“The early generations of ADCs demonstrated significant potency, but considerable room remains for innovation to generate highly effective ADCs with an improved safety profile,” CSO Ronald Herbst said in a statement.